H. medicinalis Hydramacin (Serebrennikova Screen)
Recombinant heterologous-expression screening of candidate Hirudo medicinalis macin paralogs in E. coli — Serebrennikova 2025 (LBrHM1, NrlHM1, NrlHM2, lumbricin/macin families).
Preclinical / mechanisticLast updated: 2026-05-28 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Recombinant heterologous-expression screening of candidate Hirudo medicinalis macin paralogs in E. coli — Serebrennikova 2025 (LBrHM1, NrlHM1, NrlHM2, lumbricin/macin families).
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Antibiotic stewardship
Clinical translation limit
Heterologous-expression antibacterial activity does NOT establish clinical efficacy. No FDA-approved derivative; expression in E. coli introduces non-native PTMs.
Molecular Profile
- Category
- Antimicrobial
- Evidence tier
- Preclinical
- Source species
- Hirudo medicinalis
- Discovered
- 2025 · Serebrennikova M et al.
Biological Targets
- → bacterial membrane (gram-positive, gram-negative); Bacillus subtilis
Key Citations
- Serebrennikova M et al. (2025), Int J Mol Sci · PMID 40725149
External Resources
Related Antimicrobial Compounds
Theromacin
Antimicrobial peptide active against Gram-negative bacteria — innate immunity of leech.
Theromyzin
Antimicrobial peptide; structural analogue of mammalian defensin family.
Macrostomin
Antimicrobial peptide active against Gram-positive bacteria — amphipathic alpha-helix.
Hirunipins
Newly-characterized antimicrobial peptide family (Kumar 2025) — candidate next-generation antibiotics against AMR pathogens.